# US 6,730,329 B1 · Zinc containing compositions for anti-viral use

> Agents: this data is available as JSON from the patentgrep API and MCP server — see https://patentgrep.com/llms.txt

- Number: US 6,730,329 B1
- Document ID: US6730329B1
- Status: Granted
- Kind: B1
- Application number: 10/083,007
- Filed: 2002-02-26
- Granted: 2004-05-04
- Earliest claimed: 2001-06-05
- Inventors: Jeffrey B. Smith
- Web page: https://patentgrep.com/patent/US6730329B1

## CPC

- A61K 9/0014: {Skin, i.e. galenical aspects of topical compositions (non-active ingredients are additionally classified in A61K47/00; A61K9/0009, A61K9/0021, A61K9/7015, A61K9/7023 take precedence; cosmetic preparations A61K8/00, A61Q; preparations for wound dressings or bandages A61L26/00)}
- A61K 9/0034: {Urogenital system, e.g. vagina, uterus, cervix, penis, scrotum, urethra, bladder; Personal lubricants}
- A61K 31/01: Hydrocarbons
- A61K 31/045: Hydroxy compounds, e.g. alcohols; Salts thereof, e.g. alcoholates
- A61K 31/05: Phenols {(cannabinoids A61K31/658)}
- A61K 31/315: Zinc compounds
- A61K 31/60: Salicylic acid; Derivatives thereof
- A61K 33/30: Zinc; Compounds thereof
- A61K 36/886: Aloeaceae (Aloe family), e.g. aloe vera
- A61K 45/06: Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
- A61P 31/12: Antivirals
- A61P 31/22: for herpes viruses
- A61K 47/06: Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K 47/10: Alcohols; Phenols; Salts thereof, e.g. glycerol; Polyethylene glycols [PEG]; Poloxamers; PEG/POE alkyl ethers
- A61K 47/14: Esters of carboxylic acids, e.g. fatty acid monoglycerides, medium-chain triglycerides, parabens or PEG fatty acid esters
- A61K 47/44: Oils, fats or waxes according to two or more groups of A61K47/02-A61K47/42; Natural or modified natural oils, fats or waxes, e.g. castor oil, polyethoxylated castor oil, montan wax, lignite, shellac, rosin, beeswax or lanolin (synthetic glycerides, e.g. medium-chain triglycerides, A61K47/14)
- Y02A 50/30: Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change
- A61K: PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES (devices or methods specially adapted for bringing pharmaceutical products into particular physical or administering forms A61J3/00; chemical aspects of, or use of materials for deodorisation of air, for disinfection or sterilisation, or for bandages, dressings, absorbent pads or surgical articles A61L; soap compositions C11D)
- A61P: SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- Y02A: TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE

## Abstract

One aspect of the invention relates to anti-viral composition containing at least one zinc compound and at least one phenolic antioxidant (and optionally other ingredients such as at least one analgesic) at least one hydrocarbyl containing compound, and water. Another aspect of the invention relates to a method of treating lesionous symptoms of a viral infection involving applying an effective amount of the zinc containing anti-viral composition to the lesions.

## Claims

### Claim 1

A method of treating lesionous symptoms of a viral infection, comprising:
applying an effective amount of a zinc containing composition to the lesions, the zinc containing composition comprising about 0.005% by weight or more and about 20% by weight or less of at least one zinc compound, about 0.001% by weight or more and about 20% by weight or less of at least one phenolic antioxidant selected from the group consisting of a butylated hydroxytoluene, 2(3)-tert-butyl-4-methoxyphenol, 2,6-di-tert-butyl-4-cumylphenol, 2,6-di-tert-butyl-4-nonylphenol, 2,6-dicumylphenol, 2,6-di-tert-butyl-4-isooctylphenol, and 4,4′-methylene-bis(2,6-di-tert-butylphenol), and a pharmaceutically acceptable adjuvant.

### Claim 2 (depends on 1)

The method of claim 1, wherein the zinc containing composition is applied to lesions on skin or to lesions on mucous membranes.

### Claim 3 (depends on 1)

The method of claim 1, wherein the zinc compound comprises at least one selected from the group consisting of zinc acetate, zinc citrate, zinc sulfate, zinc nitrate, zinc carbonate, zinc tartrate, zinc maleate, zinc lactate, zinc oleate, zinc benzoate, zinc glycerate, zinc glycolate, zinc oxyacetate, and hydrates thereof.

### Claim 4 (depends on 1)

The method of claim 1, wherein the butylated hydroxytoluene comprises at least one selected from the group consisting of 2,6-di-tert-butyl-4-methylphenol and 2,2′-methylene-bis(4-methyl-6-tert-butylphenol).

### Claim 5 (depends on 1)

The method of claim 1, wherein the pharmaceutically acceptable adjuvant comprises at least one hydrocarbyl containing compound and water, and the zinc containing composition comprises about 5% by weight or more and about 80% by weight or less of at least one hydrocarbyl containing compound and about 0.1% by weight or more and about 60% by weight or less of water.

### Claim 6 (depends on 1)

The method of claim 1, wherein the effective amount of the zinc containing composition is applied by forming a film over the lesions having a thickness from about 0.1 μm to about 1 mm.

### Claim 7 (depends on 1)

The method of claim 1, wherein a weight ratio of the phenolic antioxidant to the zinc compound is from about 0.75:1 to about 4:1.

### Claim 8 (depends on 1)

The method of claim 1, wherein the zinc containing composition further comprises tocotrienol.

### Claim 9

A method for the topical treatment of herpes infections in humans, comprising applying to an area of skin or mucous membrane infected with herpes an effective amount of a zinc containing composition comprising about 0.01% by weight or more and about 10% by weight or less of at least one zinc salt, about 0.005% by weight or more and about 10% by weight or less of at least one phenolic antioxidant selected from the group consisting of a butylated hydroxytoluene, 2(3)-tert-butyl-4-methoxyphenol, 2,6-di-tert-butyl-4-cumylphenol, 2,6-di-tert-butyl-4-nonylphenol, 2,6-dicumylphenol, 2,6-di-tert-butyl-4-isooctylphenol, and 4,4′-methylene-bis(2,6-di-tert-butylphenol), and a pharmaceutically acceptable adjuvant.

### Claim 10 (depends on 9)

The method of claim 9, wherein the zinc containing composition is applied to a lesionous area of skin or mucous membrane.

### Claim 11 (depends on 9)

The method of claim 9, wherein the butylated hydroxytoluene comprises at least one selected from the group consisting of 2,6-di-tert-butyl-4-methylphenol and 2,2′-methylene-bis(4-methyl-6-tert-butylphenol).

### Claim 12 (depends on 9)

The method of claim 9, wherein a weight ratio of the phenolic antioxidant to the zinc salt is from about 1:1 to about 3:1.

### Claim 13 (depends on 9)

The method of claim 9, wherein the zinc containing composition further comprises tocotrienol.

### Claim 14

A method of treating lesionous symptoms of a viral infection, comprising:
applying an effective amount of a zinc containing composition to the lesions, the zinc containing composition comprising about 0.005% by weight or more and about 20% by weight or less of at least one zinc compound, about 0.001% by weight or more and about 20% by weight or less of at least one butylated hydroxytoluene, and a pharmaceutically acceptable adjuvant; and
adhering to at least one of a low arginine diet and a high lysine diet.

### Claim 15

A method for the topical treatment of herpes infections in humans, comprising:
applying to an area of skin or mucous membrane infected with herpes an effective amount of a zinc containing composition comprising about 0.01% by weight or more and about 10% by weight or less of at least one zinc salt, about 0.005% by weight or more and about 10% by weight or less of at least one butylated hydroxytoluene, and a pharmaceutically acceptable adjuvant; and
adhering to at least one of a low arginine diet and a high lysine diet.

### Claim 16

A method of treating symptoms of a viral infection, comprising:
applying an effective amount of a zinc containing composition to the lesions, the zinc containing composition comprising about 0.005% by weight or more and about 20% by weight or less of at least one zinc compound, the zinc compound comprises at least one selected from the group consisting of zinc, zinc chloride, zinc acetate, zinc citrate, zinc sudoxicam, zinc sulfate, zinc nitrate, zinc carbonate, zinc tartrate, zinc maleate, zinc lactate, zinc aminoacetate, zinc aspartate, zinc glutamate, zinc propionate, zinc oleate, zinc benzoate, zinc butyrate, zinc formate, zinc glycerate, zinc glycolate, zinc oxide, zinc ethylenediamine tetraacetate, zinc pentosan polysulfate, zinc oxyacetate, and hydrates thereof, about 0.001% by weight or more and about 20% by weight or less of at least one phenolic antioxidant selected from the group consisting of a butylated hydroxytoluene, 2(3)-tert-butyl-4-methoxyphenol, 2,6-di-tert-butyl-4-cumylphenol, 2,6-di-tert-butyl-nonylphenol, 2,6-dicumylphenol, 2,6-di-tert-butyl-4-isooctylphenol, and 4,4′-methylene-bis(2,6-di-tert-butylphenol), and a pharmaceutically acceptable adjuvant.

### Claim 17 (depends on 16)

The method of claim 16, wherein the zinc containing composition is applied to a lesionous area of skin or mucous membrane.

### Claim 18 (depends on 16)

The method of claim 16, wherein the phenolic antioxidant comprises at least one butylated hydroxytoluene selected from the group consisting of 2,6-di-tert-butyl-4-methylphenol and 2,2′-methylene-bis(4-methyl-6-tert-butylphenol) and a weight ratio of the butylated hydroxytoluene to the zinc compound is from about 0.75:1 to about 4:1.

### Claim 19 (depends on 16)

The method of claim 16, wherein the zinc containing composition further comprises tocotrienol.

### Claim 20 (depends on 16)

The method of claim 16, further comprising adhering to at least one of a low arginine diet and a high lysine diet.
